Journal
CANCER TREATMENT REVIEWS
Volume 71, Issue -, Pages 8-18Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2018.09.005
Keywords
Melanoma; Biomarker; ctDNA; BRAF; Immunotherapy
Categories
Funding
- Novartis Pharmaceuticals Corporation
Ask authors/readers for more resources
The treatment armamentarium for patients with metastatic melanoma has increased substantially over the past decade with the regulatory approval of targeted BRAF + MEK inhibitors and immune checkpoint inhibitors, which have vastly improved long-term outcomes. Recently, these advances have been rapidly translated to the high-risk adjuvant setting. Primary and acquired resistance to both immune and molecularly targeted agents, however, remains a challenge. Therefore, biomarkers predictive of response to therapy that can be assessed prior to initiation of treatment and early during the course of therapy are critical. Equally important is on-treatment biomarker monitoring that may predict the likelihood of treatment failure and disease relapse. This review will summarize recent advances in the understanding of biomarkers for patients with advanced melanoma, emphasizing emerging baseline predictive factors and on-treatment monitoring of biomarkers that aim to establish truly personalized treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available